<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>5028</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-07-03</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Sustaining the Integration of Social Objectives Over Time: A Case-Based Analysis of Access to Medicine in the Pharmaceutical Industry</title>
    <abstract language="eng">Companies increasingly seek to strategically integrate social objectives in commercial activities to address societal challenges, yet little is known about how companies can sustain such a commitment over time. To address this question, we conduct a case-based, abductive study of two pharmaceutical companies widely considered industry leaders in facilitating access to medicine over a 20-year period (2000–2019). We identify product and operation-level integration as distinct types of integration efforts enacted by these companies. Tracing the intraorganizational dynamics associated with these efforts, we theorize that sustained integration is contingent on companies’ ability to respond to and address the challenges specific to product and operation-level integration. The theoretical framework we develop contributes to an emerging debate on the potential of companies to make progress on societal challenges by strategically integrating social objectives, including but not limited to those related to global health.</abstract>
    <parentTitle language="eng">Business &amp; Society</parentTitle>
    <identifier type="doi">10.1177/00076503231182667</identifier>
    <note>Open Access publication is funded by the Hertie School Library</note>
    <enrichment key="opus.source">publish</enrichment>
    <licence>Metadaten / metadata</licence>
    <author>Tobias Bünder</author>
    <submitter>Terri Sullivan</submitter>
    <author>Nikolas Rathert</author>
    <author>Johanna Mair</author>
    <collection role="Faculty" number=""/>
    <collection role="OA_funding" number="">Open Access publication is funded by the Hertie School Library</collection>
    <thesisPublisher>Hertie School</thesisPublisher>
  </doc>
  <doc>
    <id>4981</id>
    <completedYear/>
    <publishedYear>2022</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>300</pageFirst>
    <pageLast>319</pageLast>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>bookpart</type>
    <publisherName>Edward Elgar</publisherName>
    <publisherPlace>Cheltenham</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-05-31</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Understanding firm- and field-level change toward sustainable development: insights from the pharmaceutical industry and access to medicines, 1960‒2020</title>
    <abstract language="eng">Insufficient access to medicines is a persistent global problem that affects billions of people in low- and middle-income countries. In this chapter, we use access to medicines as a case to understand how business can become instrumental in making progress on persistent and global problems we associate with sustainable development. We examine the emergence and evolution of access to medicines as a mandate for the pharmaceutical industry to contribute to sustainable development. More specifically, we trace the historical developments of corporate social initiatives in the industry and revisit existing research on access to medicines in management and related fields. We then introduce three distinct analytical perspectives - field emergence and change, firm heterogeneity, organizational processes - to examine access to medicine, expose managerial challenges and offer a research agenda that helps to advance research on access to medicines and, more generally, on corporate efforts to address pressing global problems subsumed under the Sustainable Development Goals.</abstract>
    <parentTitle language="eng">Handbook on the Business of Sustainability</parentTitle>
    <identifier type="isbn">9781839105333</identifier>
    <identifier type="doi">10.4337/9781839105340.00025</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">false</enrichment>
    <licence>Metadaten / metadata</licence>
    <author>Tobias Bünder</author>
    <submitter>Geena Carlisle</submitter>
    <editor>Gerard George</editor>
    <author>Nikolas Rathert</author>
    <editor>Martine Haas</editor>
    <author>Johanna Mair</author>
    <editor>Havovi Joshi</editor>
    <editor>Anita McGahan</editor>
    <editor>Paul Tracey</editor>
    <collection role="HertieResearch" number="">Publications PhD Researchers</collection>
    <collection role="Faculty" number=""/>
    <thesisPublisher>Hertie School</thesisPublisher>
  </doc>
</export-example>
